The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
Open accessAbstract
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs.Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs.Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice.Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19.We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.Nonstandard abbreviations used: indoleamine 2,3-dioxygenase (IDO); 1-methyl-D-tryptophan (1MT); mixed leukocyte reaction (MLR); plasmacytoid DC (pDC); regulatory T cell (Treg); T cell receptor (TCR); tumor-draining LN (TDLN). Conflict of interest:The authors have declared that no conflict of interest exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, heightened activity of the Trp-Kyn-AhR pathway has been linked to impairment of antitumor immunity and tumor growth (16,17).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,162
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I. E., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,640
Self-citationModulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5
Nutt, S. L., Heavey, B., Rolink, A. G., & Busslinger, M. (1999) · Nature · doi:10.1038/44076 · Cited by 1,179
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y.-C., Golumbek, P. T., Ahmadzadeh, M., Jaffee, E. M., Pardoll, D. M., & Levitsky, H. I. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,159
Flagged first, then by citations
Research works printed but not linked: 2
- Cuenca, 2003, Cancer Res., 63, 9007
- Almand, 2000, Clin. Cancer Res., 6, 1755
Cited by
Sorted by citations
Items 501–600 of 877
Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer
Marmonti, E., Oliva, J., & Haymaker, C. (2022) · Cells · doi:10.3390/cells11193028 · Cited by 29
Zheng, D., Cao, Q., Lee, V. W., Wang, Y., Zheng, G., Wang, Y., Tan, T. K., Wang, C., Alexander, S. I., Harris, D. C. H., et al. (2012) · Kidney International · doi:10.1038/ki.2011.471 · Cited by 27
Xiong, A., Duan, L., Chen, J., Fan, Z., Zheng, F., Tan, Z., Gong, F., & Fang, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046230 · Cited by 29
Fotopoulou, C., Sehouli, J., Pschowski, R., von Haehling, S., Domańska, G., Braicu, E. I., Fusch, G., Reinke, P., & Schefold, J. C. (2011) · PubMed · Cited by 27
Saas, P., Varin, A., Perruche, S., & Ceroi, A. (2017) · F1000Research · doi:10.12688/f1000research.11332.2 · Cited by 27
Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?
Löb, S., & Königsrainer, A. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-007-0245-7 · Cited by 27
Hayakawa, S. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.12.010 · Cited by 27
Block, M. S., & Markovic, S. N. (2009) · American Journal of Immunology · doi:10.3844/ajisp.2009.29.49 · Cited by 29
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors
Wilczyński, J. R., & Nowak, M. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_1 · Cited by 27
Ajamian, F., Wu, Y., Ebeling, C., Ilarraza, R., Odemuyiwa, S. O., Moqbel, R., & Adamko, D. J. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12498 · Cited by 28
Molecular Evolution and Characterization of Fungal Indoleamine 2,3-Dioxygenases
Yuasa, H. J., & Ball, H. J. (2010) · Journal of Molecular Evolution · doi:10.1007/s00239-010-9412-5 · Cited by 26
Kobayashi, N., Kubota, K., Kato, S., Watanabe, S., Shimamura, T., Kirikoshi, H., Saito, S., Ueda, M., Endo, I., lnayama, Y., et al. (2010) · Pancreatology · doi:10.1159/000308966 · Cited by 26
Mengoni, M., Braun, A. D., Gaffal, E., & Tüting, T. (2020) · International Journal of Cancer · doi:10.1002/ijc.33252 · Cited by 29
Heidari, F., Ramezani, A., Erfani, N., & Razmkhah, M. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1836176 · Cited by 25
Mascanfroni, I. D., Cerliani, J. P., Dergan‐Dylon, S., Croci, D. O., Ilarregui, J. M., & Rabinovich, G. A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.021 · Cited by 27
Wang, X. (2010) · Molecular Medicine Reports · doi:10.3892/mmr.2010.395 · Cited by 25
Williams, D. E., Steinø, A., de Voogd, N. J., Mauk, A. G., & Andersen, R. J. (2012) · Journal of Natural Products · doi:10.1021/np300345j · Cited by 25
Lessons from Cancer Immunoediting in Cutaneous Melanoma
Aris, M., Barrio, M. M., & Mordoh, J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/192719 · Cited by 25
Strategies and challenges in eliciting immunity to melanoma
Ferguson, A. R., Nichols, L. A., Zarling, A. L., Thompson, E. D., Brinkman, C. C., Hargadon, K. M., Bullock, T. N. J., & Engelhard, V. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00620.x · Cited by 24
Posttranslational modification of indoleamine 2,3-dioxygenase
Fujigaki, H., Seishima, M., & Saito, K. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-5946-2 · Cited by 24
Li, J., Southerland, L. T., Lu, Y., Darlak, K. A., Giver, C. R., McMillin, D. W., Harris, W. A. C., Jaye, D. L., & Waller, E. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900155 · Cited by 24
Immunotherapeutic strategies employing RNA interference technology for the control of cancers
Mao, C.-P., Hung, C., & Wu, T. ‐. (2006) · Journal of Biomedical Science · doi:10.1007/s11373-006-9131-5 · Cited by 24
Immune microenvironment of tumor-draining lymph nodes: insights for immunotherapy
Wei, J., Li, D., Long, H., & Han, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1562797 · Cited by 26
Ufermann, C.-M., Domröse, A., Babel, T., Tersteegen, A., Cengiz, S. C., Eller, S. K., Spekker, K., Sorg, U. R., Förster, I., & Däubener, W. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00184 · Cited by 23
Zhang, S.-W., Wang, H., Ding, X., Xiao, Y.-L., Shao, Z.-M., You, C., Gu, Y., & Jiang, Y. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.03.009 · Cited by 23
Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation
Cuevas, E. S., Saas, P., & Aspord, C. (2023) · Cancers · doi:10.3390/cancers15082206 · Cited by 24
Targeting cGAS/STING signaling-mediated myeloid immune cell dysfunction in TIME
Kumar, V., Bauer, C., & Stewart, J. H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00942-2 · Cited by 23
Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice
Nakamura, N., Hara, T., Shimizu, M., Mabuchi, R., Nagano, J., Ohno, T., Kochi, T., Kubota, M., Shirakami, Y., Goto, N., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1835-8 · Cited by 23
Immune regulation by non-lymphoid cells in transplantation
Dugast, A., & Vanhove, B. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03877.x · Cited by 23
TGF-β signalling and immunity in prostate tumourigenesis
Diener, K. R., Need, E. F., Buchanan, G., & Hayball, J. D. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903544507 · Cited by 23
Metabolism, LXR/LXR ligands, and tumor immune escape
Russo, V. E. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411198 · Cited by 26
Özer, Z., Gök, S., Altan, H., & Severcan, F. (2014) · Applied Spectroscopy · doi:10.1366/13-07165 · Cited by 23
The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection
Makala, L. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-5 · Cited by 24
Ninomiya, S., Hara, T., Tsurumi, H., Goto, N., Saito, K., Seishima, M., Takami, T., & Moriwaki, H. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.643472 · Cited by 23
Ahmed, D., & Cassol, E. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.037 · Cited by 24
Lanzinger, M., Jürgens, B., Hainz, U., Dillinger, B., Raberger, J., Fuchs, D., & Heitger, A. (2012) · European Journal of Immunology · doi:10.1002/eji.201141765 · Cited by 23
Chen, X., Liu, L., Yang, P., Wu, C. Y., Jin, H., Lin, X., Li, B., Zhou, H., Huang, X., & Zhu, L. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.08.006 · Cited by 23
The first indoleamine-2,3-dioxygenase-1 (IDO1) inhibitors containing carborane
Austin, C., Kahlert, J. U., Issa, F., Reed, J. H., Smith, J. R., Ioppolo, J. A., Ong, J. A., Jamie, J. F., Hibbs, D. E., & Rendina, L. M. (2014) · Dalton Transactions · doi:10.1039/c4dt00444b · Cited by 22
Popp, F., Capino, I., Bartels, J., Damanakis, A. I., Li, J., Datta, R. R., Löser, H., Zhao, Y., Quaas, A., Lohneis, P., et al. (2021) · Cancers · doi:10.3390/cancers13112689 · Cited by 22
Engineering better immunotherapies via RNA interference
Sioud, M. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29754 · Cited by 22
Fang, W., Shi, M., Meng, C., Li, D., & Peng, J. (2016) · Scientific Reports · doi:10.1038/srep26984 · Cited by 23
Alahdal, M., Xing, Y., Tang, T., & Liang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-28238-8 · Cited by 22
Habibi, D., Jalili, R. B., Forouzandeh, F., Ong, C. J., & Ghahary, A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22220 · Cited by 23
Wang, C., Shi, Y., Min, Y., Zhu, X., Guo, C., Peng, J., Dong, X.-Y., Qin, P., Sun, J., & Hou, M. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9525-7 · Cited by 22
Wang, Y., Hu, G.-F., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136259 · Cited by 21
Tomei, S., Ibnaof, O., Ravindran, S., Ferrone, S., & Maccalli, C. (2021) · Cancers · doi:10.3390/cancers13071674 · Cited by 21
Wilfong, E. M., Bartkowiak, T., Vowell, K. N., Westlake, C. S., Irish, J. M., Kendall, P. L., Crofford, L. J., & Bonami, R. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.756018 · Cited by 21
Chilosi, M., Doglioni, C., Ravaglia, C., Martignoni, G., Salvagno, G. L., Pizzolo, G., Bronte, V., & Poletti, V. E. (2022) · Biomedicines · doi:10.3390/biomedicines10061332 · Cited by 22
Modulation of T cell function and survival by the tumor microenvironment
Mani, N. L., Andrews, D., & Obeng, R. C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1191774 · Cited by 22
How tumors might withstand γδ T-cell attack
Capietto, A.-H., Martinet, L., & Fournié, J. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0705-7 · Cited by 24
Genescà, M., Ma, Z.-M., Wang, Y., Assaf, B. T., Qureshi, H., Fritts, L., Huang, Y., McChesney, M. B., & Miller, C. J. (2012) · Journal of Virology · doi:10.1128/jvi.00532-12 · Cited by 21
Molecular evolution of bacterial indoleamine 2,3-dioxygenase
Yuasa, H. J., Ushigoe, A., & Ball, H. J. (2011) · Gene · doi:10.1016/j.gene.2011.06.002 · Cited by 23
Improving T cell therapy for cancer
Foster, A. E., & Rooney, C. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.215 · Cited by 22
The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer
Busselaar, J., Sijbranda, M., & Borst, J. G. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106938 · Cited by 21
Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms
Roussel, X., Garnache‐Ottou, F., & Renosi, F. (2022) · Cancers · doi:10.3390/cancers14143545 · Cited by 21
Korać, K., Rajasekaran, D., Sniegowski, T., Schniers, B. K., Ibrahim, A., & Bhutia, Y. D. (2022) · Biochemical Journal · doi:10.1042/bcj20210851 · Cited by 21
Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting
Achmad, H., Ibrahim, Y. S., Al‐Taee, M. M., Gabr, G. A., Riaz, M. W., Alshahrani, S. H., Ramírez‐Coronel, A. A., Jalil, A. T., Budi, H. S., Sawitri, W., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109434 · Cited by 20
Noh, K. T., Son, K. H., Jung, I. D., Kang, T. H., Choi, C. H., & Park, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.628578 · Cited by 20
Regional lymphatic immunity in melanoma
Grotz, T. E., Mansfield, A. S., Jakub, J. W., & Markovic, S. N. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834e1f33 · Cited by 20
Aung, L. L., Brooks, A., Greenberg, S. A., Rosenberg, M. L., Dhib-Jalbut, S. S., & Balashov, K. E. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.05.013 · Cited by 20
Davar, D., & Bahary, N. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0547-9 · Cited by 20
Berrong, Z., Mkrtichyan, M., Ahmad, S., Webb, M., Mohamed, E. T., Gg, O., Matevosyan, A., Shrimali, R. K., Eid, R. A., Hammond, S. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0223 · Cited by 20
Myeloid and Plasmacytoid Dendritic Cells and Cancer – New Insights
Gulubova, M. V., Ivanova, K. V., Hadzhi, M., Chonov, D., Ignatova, M. M., & Ananiev, J. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.735 · Cited by 20
Tang, T. J., Vukosavljevic, D. N., Janssen, H. L. A., Binda, R. S., Mancham, S., Tilanus, H. W., IJzermans, J. N. M., Drexhage, H. A., & Kwekkeboom, J. (2006) · Human Pathology · doi:10.1016/j.humpath.2005.11.007 · Cited by 20
Emerging strategies in regulatory T-cell immunotherapies.
Gajewski, T. F., Chesney, J. A., & Curriel, T. J. (2009) · PubMed · Cited by 20
Li, R., Zheng, Q.-H., Deng, Q.-P., Wang, Y., Yang, H., Shen, J., Liu, Y., & Zhou, J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00999 · Cited by 19
Ruben, J. M., García-Romo, G. S., Breman, E., van der Kooij, S. W., Redeker, A., Arens, R., & van Kooten, C. (2017) · Kidney International · doi:10.1016/j.kint.2017.08.006 · Cited by 19
Saas, P., Varin, A., Perruche, S., & Ceroi, A. (2017) · F1000Research · doi:10.12688/f1000research.11332.1 · Cited by 20
Impact of sidedness of colorectal cancer on tumor immunity
Takasu, C., Nishi, M., Yoshikawa, K., Tokunaga, T., Kashihara, H., Yoshimoto, T., & Shimada, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240408 · Cited by 19
Grobben, Y., de Man, J., van Doornmalen, A. M., Müller, M., Willemsen‐Seegers, N., Vu‐Pham, D., Mulder, W. R., Prinsen, M. B. W., de Wit, J., Sterrenburg, J. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609490 · Cited by 19
Regulation of dendritic cell function by Fc-γ-receptors and the neonatal Fc receptor
Macri, C., Morgan, H., Villadangos, J. A., & Mintern, J. D. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.07.024 · Cited by 19
Identification of a prognostic immune‐related signature for small cell lung cancer
Xie, Q., Chu, H., Yi, J., Yu, H., Gu, T., Guan, Y., Liu, X., Liang, J., Li, Y., & Wang, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4402 · Cited by 19
Li, L., Huang, L., Lemos, H. D. P., Mautino, M. R., & Mellor, A. L. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00109 · Cited by 20
Self-citationp-Coumaric acid inhibits indoleamine 2, 3-dioxygenase expression in murine dendritic cells
Kim, S.-I., Jeong, Y.-I., Jung, I. D., Lee, J. S., Lee, C.-M., Yoon, M., Seong, E.-Y., Kim, J., Lee, J.-D., & Park, Y. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.01.020 · Cited by 19
Self-citationThe Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa
Byakwaga, H., Hunt, P. W., Laker‐Oketta, M., Glidden, D. V., Huang, Y., Bwana, B. M., Mocello, A. R., Bennett, J., Walusansa, V., Dollard, S. C., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000747 · Cited by 19
Norouzian, M., Mehdipour, F., Ashraf, M. J., Khademi, B., & Ghaderi, A. A. (2022) · BMC Immunology · doi:10.1186/s12865-022-00530-3 · Cited by 18
Cheng, H., Chen, W., Lin, Y., Zhang, J., Song, X., & Zhang, D. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00125-3 · Cited by 22
Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis
Cao, W. (2014) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000212 · Cited by 18
Low dose Zebularine treatment enhances immunogenicity of tumor cells
Liu, H., Xue, Z., Sjögren, H. O., Salford, L. G., & Widegren, B. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.07.013 · Cited by 18
Cancer vaccines inducing antibody production: more pros than cons
Jensen‐Jarolim, E., & Singer, J. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.105 · Cited by 18
Tumor-Induced Immune Suppression
Gabrilovich, D. I., & Hurwitz, A. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3 · Cited by 18
Ward, F. J., Dahal, L. N., & Eid, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02182 · Cited by 18
Accumulation of exhausted CD8+ T cells in extramammary Paget’s disease
Iga, N., Otsuka, A., Yamamoto, Y., Nakashima, C., Honda, T., Kitoh, A., Nakajima, S., Egawa, G., Nomura, T., Dainichi, T., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211135 · Cited by 18
Proteostasis in dendritic cells is controlled by the PERK signaling axis independently of ATF4
Mendes, A. V., Gigan, J. P., Rodrígues, C. R., Choteau, S. A., Sanséau, D., Barros, D., Almeida, C. R., Camosseto, V., Chasson, L., Chasson, L., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.202000865 · Cited by 20
Zhu, X., Yin, X., Hei, G., Wei, R., Guo, Q., Zhao, L., Zhang, Z., Chu, C., Fu, X., Xu, K., et al. (2021) · Molecular Human Reproduction · doi:10.1093/molehr/gaab044 · Cited by 18
Amino Acid Deprivation Links BLIMP-1 to the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase
Barnes, N. A., Stephenson, S., Tooze, R. M., & Doody, G. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803480 · Cited by 19
The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma
Oosterhoff, D., Sluijter, B. J. R., Hangalapura, B. N., & de Gruijl, T. D. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_136 · Cited by 18
Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction
Lee, J. H., Chen, Y., Chan, J. L. ‐., Qian, Y., & Goydos, J. S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0982-x · Cited by 18
Self-citationPlasmacytoid Dendritic Cells: Neglected Regulators of the Immune Response to Staphylococcus aureus
Bekeredjian‐Ding, I., Greil, J., Ammann, S., & Parčina, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00238 · Cited by 21
A subset of dendritic cells express joining chain (J‐chain) protein
Källberg, E., & Leanderson, T. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02733.x · Cited by 18
Kim, Y. H., Choi, B. K., Kang, W. J., Kim, K. H., Kang, S. W., Mellor, A. L., Munn, D. H., & Kwon, B. S. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0408246 · Cited by 18
Self-citationNanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment
Wang, J., Ma, J., Tai, Z., Li, L., Zhang, T., Cheng, T., Yu, J., Zhu, Q., Bao, L., & Chen, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s434582 · Cited by 17
Enhancing Leukemia Treatment: The Role of Combined Therapies Based on Amino Acid Starvation
Chen, C., & Zhang, J. (2024) · Cancers · doi:10.3390/cancers16061171 · Cited by 18
Miller, H. L., Andhey, P. S., Swiecki, M. K., Rosa, B. A., Zaitsev, K., Villani, A., Mitreva, M., Artyomov, M. N., Gilfillan, S., Cella, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021364118 · Cited by 17
The role of indoleamine 2,3‐dioxygenase in allergic disorders
Esmaeili, S., & Hajavi, J. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-07067-5 · Cited by 17
Forrester, S. J., Goundry, A., Dias, B. T., Leal-Calvo, T., Moraes, M. O., Kaye, P. M., Mottram, J. C., & Lima, A. P. C. A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00679-22 · Cited by 21
Normal development and function of dendritic cells in mice lacking IDO-1 expression
de Faudeur, G., Trez, C. D., Muraille, É., & Léo, O. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.006 · Cited by 17
Chen, C.-A., Chang, M., Sun, W.-Z., Chen, Y.-L., Chiang, Y.-C., Hsieh, C.-Y., Chen, S. M., Hsiao, P., & Cheng, W.-F. (2009) · Gene Therapy · doi:10.1038/gt.2009.31 · Cited by 17
Antisense therapy for restenosis following percutaneous coronary intervention
Kipshidze, N. N., Tsapenko, M. V., Iversen, P. L., & Burger, D. R. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.79 · Cited by 17
Andersen, M. H. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02710-8 · Cited by 16
Metadata
- Authors
- Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L.
- Affiliations
- Augusta University (US)
- University of South Florida (US)
- Corresponding author
- Munn, David H.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-15
- Volume
- 114
- Issue
- 2
- Pages
- 280-290
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2143565660
- Cited by
- 852
- References
- 85
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 32 · 2021: 37 · 2020: 34 · 2019: 29 · 2018: 31 · 2017: 40 · 2016: 27 · 2015: 45 · 2014: 38 · 2013: 53 · 2012: 39
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Carlos and Marguerite Mason Trust
- National Institutes of Health
- National Cancer Institute (R01CA096651, R01 CA103220)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD041187)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- indoleamine 2,3-dioxygenase, plasmacytoid dendritic cells, tumor-draining lymph nodes, immunosuppression, T cell anergy, tumor antigen presentation, CD19, 1-methyl-D-tryptophan, antitumor immunity, regulatory T cells, mixed lymphocyte reaction
- MeSH terms
- Animals, Antigen-Presenting Cells, Dendritic Cells, Female, Humans, Immunosuppression Therapy, Lymph Nodes, Lymphocyte Activation, Mice, Inbred Strains, Neoplasms, Random Allocation, T-Lymphocytes, Tryptophan Oxygenase, Survival Rate, Mice, Knockout, Antigens, CD19, Adoptive Transfer, CD11c Antigen, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
